dexamethasone,lenalidomide,bortezomib
takeda
['determination', 'mmsm']
determination trial - rvd asct and r maintenance to progression resulted in the longest median pfs reported for each approach, and a highly significant 21.4-mo gain in median pfs benefit using rvd + asct. no os advantage has been observed to date. nct01208662 #asco22 #mmsm 
Multiple Myeloma Education Platform for Myeloma Community